Regulation of TET function by PROSER1 in development and hematologic malignancies
Epigenomics · 03.08.2026 · 18 (8) · 1011-1019
DOI: 10.1080/17501911.2026.2698006 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Epigenomics, online erschienen am 09.07.2026. Verfasst von Xiang Li und 1 weiteren Autor:innen. Beteiligte Einrichtung: Division of Molecular, Cellular, and Developmental Biology, University of Dundee, Dundee, UK. Hauptthemen laut MEDLINE: Hematologic Neoplasms, Proto-Oncogene Proteins, DNA-Binding Proteins. Die Arbeit nennt 60 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: Cancer Research UK, China Scholarship Council.
Abstract (Originalsprache)
Ten eleven translocation (TET) proteins are central regulators of DNA methylation homeostasis and play essential roles in development and disease, including hematopoietic malignancies. Among the three TET family members, mutations in TET2 are frequently observed in hematologic disorders. TET enzymes catalyze the iterative oxidation of 5-methylcytosine (5mC) to 5-hydroxymethylcytosine (5hmC) and further oxidized derivatives, enabling DNA demethylation. Beyond catalysis, TET proteins also perform important non-enzymatic functions mediated through interactions with diverse protein partners, highlighting the importance of defining their regulatory interactome. Previous studies identified several TET-associated factors, including O-Linked N-acetylglucosamine transferase (OGT), members of the Drosophila behavior/human splicing (DBHS) protein family, and proline and serine-rich protein 1 (PROSER1). However, these interactions were largely considered independently. Recent findings now demonstrate that TET proteins, OGT, PROSER1, and DBHS proteins assemble into a higher-order regulatory unit termed the TOPD (TET-OGT-PROSER1-DBHS) complex. In this review, we discuss how TOPD provides a conceptual framework for understanding multicomponent regulation of TET function, spatial control of DNA demethylation, and maintenance of epigenetic homeostasis, with implications for developmental syndromes and hematopoiesis. TET proteins help control how DNA is chemically marked inside cells. These DNA marks influence which genes are turned on or off, making TET proteins important for normal development and for preventing blood cancers. TET proteins remove DNA methylation marks through a series of chemical steps, helping keep gene activity balanced. However, their role is not limited to this enzyme activity. TET proteins also work by interacting with other proteins, which helps guide where and how they act in the genome. Understanding these protein partnerships is therefore essential for explaining how TET proteins function in health and disease. Several proteins have been identified as TET partners, including OGT, DBHS proteins, and PROSER1. Until recently, these interactions were studied separately. New evidence now shows that these proteins come together to form a single regulatory assembly called the TOPD complex. This is the first time TOPD has been recognized as an integrated multicomponent complex. In this review, we explain how the TOPD complex helps coordinate TET activity, maintain stable DNA methylation patterns, and influence development and blood cell formation.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Division of Molecular, Cellular, and Developmental Biology, University of Dundee, Dundee, UK.
ORCID-Profile: Xiang Li, Kasper D Rasmussen
Förderung
- Cancer Research UK
- China Scholarship Council
Zitieren
APA
Li, X., & Rasmussen, K. D. (2026). Regulation of TET function by PROSER1 in development and hematologic malignancies. Epigenomics, 18(8), 1011-1019. https://doi.org/10.1080/17501911.2026.2698006
Vancouver
Li X, Rasmussen KD. Regulation of TET function by PROSER1 in development and hematologic malignancies. Epigenomics. 2026;18(8):1011-1019. doi:10.1080/17501911.2026.2698006
BibTeX
@article{Li2026,
author = {Li, Xiang and Rasmussen, Kasper D},
title = {Regulation of TET function by PROSER1 in development and hematologic malignancies},
journal = {Epigenomics},
year = {2026},
volume = {18},
number = {8},
pages = {1011--1019},
doi = {10.1080/17501911.2026.2698006}
}
EUVIMED